Urinary angiotensin converting enzyme 2 is significantly increased in diabetes and diabetic nephropathy and correlates with metabolic and renal parameters, highlighting its potential as a diagnostic and prognostic biomarker.
What is the clinical significance and potential role of urinary ACE2 in the management of diabetes and diabetic nephropathy?
Urinary ACE2 is elevated in diabetic nephropathy and may serve as a relevant biomarker, though current quantification methods require further validation.
Urinary angiotensin converting enzyme 2 (ACE2) is significantly increased in diabetes and diabetic nephropathy. While studies on its clinical significance are still underway, its urinary expression, association with metabolic and renal parameters has been in the recent past considerably studied. The recent studies have demystified urine ACE2 in many ways and suggested the roles it could play in the management of diabetic nephropathy. In all studies the expression of urinary ACE2 was determined by enzyme activity assay and/with the quantification of ACE2 protein and mRNA by methods whose reliability are yet to be evaluated. This review summarizes recent findings on expression of urinary ACE2, examines its relationship with clinical parameters and highlights possible applications in management of diabetic nephropathy.
Akankwasa et al. (Fri,) conducted a review in Diabetes and diabetic nephropathy. Urinary angiotensin converting enzyme 2 (ACE2) was evaluated. Urinary angiotensin converting enzyme 2 is significantly increased in diabetes and diabetic nephropathy and correlates with metabolic and renal parameters, highlighting its potential as a diagnostic and prognostic biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: